Biovail Shareholders Approve All Proposed Resolutions.Business Editors, Health/Medical Writers TORONTO--(BW HealthWire)--Jan. 6, 2000 Biovail Corporation International (NYSE NYSE See: New York Stock Exchange :BVF)(TSE See Tokyo Stock Exchange. TSE 1. See Tokyo Stock Exchange (TSE). 2. See Toronto Stock Exchange (TSE). :BVF) announced today that at a special meeting of shareholders, the shareholders of the Corporation approved a stock split of the common shares on the basis of two common shares for each one common share held, an increase in the authorized capital from 120,000,000 common shares to an unlimited number of common shares and a change in the quorum requirements for shareholders' meetings from two shareholders holding 51 percent of the outstanding shares to two shareholders holding 25 percent of the outstanding shares. Additional common shares resulting from the stock split will be issued to shareholders of record as of the close of business on January 12, 2000 and certificates representing such shares will be mailed to shareholders on or about January 19, 2000. The shares will begin trading on a split basis on January 10, 2000 on the Toronto Stock Exchange Toronto Stock Exchange (TSE) Canada's largest stock exchange, trading approximately 1,200 company stocks and 33 options. and on January 20, 2000 on the New York Stock Exchange New York Stock Exchange (NYSE) World's largest marketplace for securities. The exchange began as an informal meeting of 24 men in 1792 on what is now Wall Street in New York City. . Biovail Corporation International is an international integrated pharmaceutical company, engaged in the formulation, clinical testing, registration and manufacture of drug products utilizing advanced drug delivery technologies. "Safe Harbor" statement under the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. To the extent any statements made in this release contain information that is not historical, these statements are essentially forward looking and are subject to risks and uncertainties, including the difficulty of predicting FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. and TPP TPP thiamine pyrophosphate. Thiamine pyrophosphate (TPP) The coenzyme containing thiamine that is essential in converting glucose to energy. Mentioned in: Beriberi TPP 1. total plasma protein. 2. approvals, acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, the regulatory environment, fluctuations in operating results and other risks detailed from time to time in the Company's filings with the U.S. Securities and Exchange Commission. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion